

Nicole D Fleming

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8035916/publications.pdf>

Version: 2024-02-01

56
papers

1,358
citations

361413

20
h-index

361022

35
g-index

56
all docs

56
docs citations

56
times ranked

1916
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1496.	3.7	6
2	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 82-89.	1.4	2
3	Clinical implications of tumor-based next-generation sequencing in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5545-5545.	1.6	0
4	Active Living After Cancer (ALAC) program: An avenue to improve physical functioning and moderate-intensity physical activity in gynecologic cancer survivors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24034-e24034.	1.6	0
5	Standardized documentation of advanced care planning to facilitate goal-concordant care in a large gynecologic oncology practice.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6574-6574.	1.6	0
6	A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5522-5522.	1.6	6
7	Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 191.e1-191.e15.	1.3	56
8	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. <i>Scientific Reports</i> , 2021, 11, 3667.	3.3	20
9	Distinct TÀcell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. <i>IScience</i> , 2021, 24, 102053.	4.1	6
10	Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 626.	3.7	26
11	A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 704.	3.7	3
12	Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 56-62.	1.4	7
13	Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 660-667.	1.4	6
14	Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, 24-31.	1.4	20
15	Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 65-71.	1.4	3
16	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3545-3555.	2.5	5
17	Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 232-237.	2.5	0
18	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 92-97.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 352-357.	2.5	8
20	A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 206-213.	3.7	13
21	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. <i>Gynecologic Oncology</i> , 2020, 158, 653-658.	1.4	29
22	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , 2020, 31, 107502.	6.4	69
23	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. <i>Gynecologic Oncology</i> , 2019, 154, 524-530.	1.4	24
24	Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. <i>Cancer</i> , 2019, 125, 3347-3353.	4.1	12
25	Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. <i>Gynecologic Oncology</i> , 2019, 154, 328-332.	1.4	6
26	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. <i>Oncotarget</i> , 2019, 10, 3533-3546.	1.8	19
27	Total and out-of-pocket costs of different primary management strategies in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 136.e1-136.e9.	1.3	25
28	National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 152, 439-444.	1.4	11
29	Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e45.	2.2	37
30	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. <i>Scientific Reports</i> , 2019, 9, 17589.	3.3	12
31	Prognostic factors impacting survival in early stage uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2019, 152, 31-37.	1.4	29
32	Evaluation and Improvement of Bottlenecking in a Multidisciplinary Oncology Clinic: An Electronic Medical Record Intervention. <i>Cureus</i> , 2019, 11, e4583.	0.5	0
33	The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1297-1310.	2.5	16
34	Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 428-432.	1.4	19
35	Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2018, 132, 545-554.	2.4	49
36	Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. <i>Gynecologic Oncology</i> , 2017, 145, 37-40.	1.4	51

#	ARTICLE	IF	CITATIONS
37	Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. <i>Gynecologic Oncology</i> , 2017, 145, 55-60.	1.4	48
38	Factors prognostic of survival in advanced-stage uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2017, 146, 27-33.	1.4	26
39	A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 146, 234-239.	1.4	171
40	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 41-46.	1.4	17
41	Treatment of Recurrent or Metastatic Uterine Adenosarcoma. <i>Sarcoma</i> , 2017, 2017, 1-9.	1.3	12
42	A non-pregnant woman with elevated beta-HCG: A case of para-neoplastic syndrome in ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2016, 17, 49-52.	0.6	10
43	Uterine Adenosarcoma: a Review. <i>Current Oncology Reports</i> , 2016, 18, 68.	4.0	62
44	Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation. <i>Gynecologic Oncology</i> , 2016, 143, 596-603.	1.4	25
45	Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer. <i>Gynecologic Oncology</i> , 2016, 142, 283-285.	1.4	11
46	Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1437-1444.	2.5	24
47	Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. <i>Gynecologic Oncology</i> , 2015, 136, 48-53.	1.4	79
48	Same-day discharge is feasible and safe in patients undergoing minimally invasive staging for gynecologic malignancies. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 186.e1-186.e8.	1.3	62
49	Improvement in quality of life after robotic surgery results in patient satisfaction. <i>Gynecologic Oncology</i> , 2015, 138, 727-730.	1.4	20
50	Postoperative Pain Scores and Narcotic Use in Robotic-assisted Versus Laparoscopic Hysterectomy for Endometrial Cancer Staging. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 1004-1010.	0.6	14
51	Ovarian Torsion After Laparoscopic Ovarian Transposition in Patients With Gynecologic Cancer: A Report of Two Cases. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 687-690.	0.6	19
52	Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence. <i>Gynecologic Oncology</i> , 2014, 135, 455-461.	1.4	84
53	Position-related injury is uncommon in robotic gynecologic surgery. <i>Gynecologic Oncology</i> , 2014, 135, 534-538.	1.4	23
54	Conversion from robotic surgery to laparotomy: A caseâ€“control study evaluating risk factors for conversion. <i>Gynecologic Oncology</i> , 2014, 134, 238-242.	1.4	19

#	ARTICLE	IF	CITATIONS
55	Robotic surgery in gynecologic oncology. <i>Current Opinion in Oncology</i> , 2012, 24, 547-553.	2.4	27
56	Operative and anesthetic outcomes in endometrial cancer staging via three minimally invasive methods. <i>Journal of Robotic Surgery</i> , 2012, 6, 337-344.	1.8	7